As reported on PharmaBiz, the U.S. Food and Drug Administration has accepted Takeda’s New Drug Application for the investigational oral therapy zasocitinib (TAK-279) and assigned the filing Priority Review status…
Takeda Pharmaceutical Company has announced breakthrough results from Phase 3 trials of zasocitinib (TAK-279), an innovative oral treatment for moderate-to-severe plaque psoriasis that offers patients a promising new option for…
Acknowledgment: This story is sponsored by Janssen Pharmaceuticals and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted,…
According to a press release from Eli Lilly and Company, the US Food and Drug Administration (FDA) recently granted market approval to Lilly's ankylosing spondylitis drug, Taltz (ixekizumab). About Ankylosing…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
